Helicobacter pylori is the primary etiologic agent involved in gastric diseases in humans with worldwide distributions. In 2005, H. pylori was identified as a microbiologic contaminant of water, and its role in gastric diseases was further assessed.
Helicobacter pylori, is the causative agent of gastritis, gastric ulcers, gastric cancer and mucosal-associated lymphoid tissue tumor (MALT). There are several treatment schemes for the eradication of this bacterium.
astric cancer is one of the most common types of cancer in the world. In Chile, the disease represents the first cause of cancer death in men and the third cause in women, where approximately 3000 individuals died every year from gastric cancer.
Chile has a 60 to 80 % rate of Helicobacter infection depending on the region; is no surprise that the mortality rate due to gastric cancer in Chile is one of the highest in America.
Little is known about serum diagnostic metabolites relate to H. pylori risk of gastric cancer (GC). We aimed to investigate the association between plasma metabolite concentrations and H. pylori infection and two cohorts of patients at risk and excluded GC.
Gastric cancer (GC) is the sixth most common cancer and the third leading cause of death due to cancer worldwide. More than a half of patients are diagnosed at advanced stage (TNM III), where 5-year overall survival rate is less than 50%.
